CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
3.980
-0.172 (-4.14%)
At close: Jun 26, 2026, 4:00 PM EDT
4.050
+0.070 (1.76%)
After-hours: Jun 26, 2026, 7:39 PM EDT
Company Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States.
It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.
The company was incorporated in 2017 and is headquartered in Houston, Texas.
CNS Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Rami Levin |
Contact Details
Address: 2100 West Loop South, Suite 900 Houston, Texas 77027 United States | |
| Phone | 800 946 9185 |
| Website | cnspharma.com |
Stock Details
| Ticker Symbol | CNSP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001729427 |
| CUSIP Number | 18978H508 |
| ISIN Number | US18978H5081 |
| Employer ID | 82-2318545 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rami Levin M.B.A. | President, Chief Executive Officer and Director |
| Christopher S. Downs CPA, CTP, FP&A | Senior Vice President of Finance |
| Steve O'Loughlin M.B.A. | Chief Financial Officer |
| Eric Faulkner M.B.A., M.Sc. | Chief Technology Officer |
| Dylan Wenke M.B.A. | Chief Business Officer |
| Dr. E. Lynne Kelley F.A.C.S., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 26, 2026 | EFFECT | Notice of Effectiveness |
| May 26, 2026 | 424B3 | Prospectus |
| May 19, 2026 | D | Notice of Exempt Offering of Securities |
| May 19, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 14, 2026 | 10-Q | Quarterly Report |
| May 4, 2026 | 8-K | Current Report |
| Apr 30, 2026 | 10-K/A | [Amend] Annual report |
| Apr 17, 2026 | SCHEDULE 13G | Filing |
| Mar 31, 2026 | 10-K | Annual Report |